The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers

Influenza Other Respir Viruses. 2022 Sep;16(5):916-925. doi: 10.1111/irv.12997. Epub 2022 May 5.

Abstract

Background: Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection.

Methods: We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to (i) measure the average incidence rate of reinfection and (ii) describe the serological immune response to the primary infection.

Results: Our cohort comprised 569 HCWs; median duration of individual follow-up was 371 days. We detected six cases of reinfection in absence of vaccination between August 21, 2020, and March 1, 2022, for a reinfection incidence rate of 4.0 per 100 person-years. Median duration of seropositivity was 415 days in symptomatics at primary infection compared with 213 days in asymptomatics (p < 0.0001). Other characteristics associated with prolonged seropositivity for IgG against the spike protein included age over 55 years, obesity, and non-Caucasian ethnicity.

Conclusions: Among unvaccinated healthcare workers, reinfection with SARS-CoV-2 following a primary infection remained rare.

Keywords: COVID-19; SARS-CoV-2; prospective studies; reinfection; serology.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • Canada / epidemiology
  • Cohort Studies
  • Health Personnel
  • Humans
  • Middle Aged
  • Prospective Studies
  • Reinfection / epidemiology
  • SARS-CoV-2

Grants and funding